How to assess the dose of Fibryga (fibrinogen) with ROTEM (Rotational Thromboelastometry)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Assessing Fibryga Dosing with ROTEM

For optimal dosing of Fibryga (fibrinogen concentrate) using ROTEM, administer 3-4 g (or 50 mg/kg) when FIBTEM A10 is ≤10 mm or MCF is <7 mm, with each gram of fibrinogen expected to increase FIBTEM by approximately 2 mm.

Understanding ROTEM-Guided Fibrinogen Replacement

Baseline Assessment and Indications

  • ROTEM provides real-time assessment of functional fibrinogen contribution to clot formation, making it preferable to laboratory fibrinogen measurement in bleeding patients 1
  • Hypofibrinogenemia is the biomarker most predictive of severe postpartum hemorrhage and is often the first coagulation factor to critically decrease during massive blood loss 2, 1
  • Fibrinogen supplementation is indicated when there are thromboelastometric signs of a functional fibrinogen deficit or plasma fibrinogen levels <1.5-2.0 g/L in the presence of significant bleeding 2, 3

ROTEM Parameters for Fibryga Dosing

  • In trauma patients, a Maximum Clot Firmness (MCF) of 7 mm on ROTEM correlates with a fibrinogen level of approximately 2 g/L 2, 1
  • FIBTEM A10 ≤10 mm is considered the threshold for fibrinogen replacement in bleeding patients 4
  • For acquired fibrinogen deficiency, the FDA-approved dosing for Fibryga is:
    • Adults: 4 g
    • Adolescents ≥12 years: 50 mg/kg
    • Children <12 years: 70 mg/kg 4

Expected Response to Fibryga Administration

  • For every gram of fibrinogen concentrate administered, expect approximately a 2-mm increase in the FIBTEM assay 1
  • A single dose of Fibryga significantly increases MCF from baseline, with a mean change of 9.7 mm one hour post-infusion 4
  • Fibryga contains a higher concentration of factor XIII (0.2 IU factor XIII per mg fibrinogen) compared to other fibrinogen concentrates, which may enhance clot firmness 1

Practical Algorithm for Fibryga Dosing with ROTEM

  1. Initial Assessment:

    • Perform baseline ROTEM assessment focusing on FIBTEM A10 or MCF 2, 1
    • If possible, obtain plasma fibrinogen level simultaneously 3
  2. Decision to Administer Fibryga:

    • Administer when FIBTEM A10 ≤10 mm or MCF <7 mm 4, 1
    • Alternatively, administer when plasma fibrinogen <1.5-2.0 g/L with significant bleeding 2, 3
  3. Initial Dosing:

    • Adults: 4 g Fibryga 4
    • Adolescents ≥12 years: 50 mg/kg 4
    • Children <12 years: 70 mg/kg 4
  4. Post-Administration Monitoring:

    • Repeat ROTEM assessment 1 hour after administration 4
    • Target FIBTEM A10 >10 mm or MCF >7 mm 1, 5
    • Target plasma fibrinogen level >200 mg/dL to limit massive transfusion requirements 5
  5. Additional Dosing:

    • Administer additional doses if FIBTEM A10 remains ≤10 mm or plasma fibrinogen ≤200 mg/dL with continued bleeding 4, 5
    • For ongoing bleeding, maintain fibrinogen levels above 200 mg/dL 5

Clinical Considerations and Caveats

Efficacy Considerations

  • A single dose of Fibryga is often sufficient to correct fibrinogen and FIBTEM A10 only when baseline fibrinogen is >100 mg/dL and FIBTEM A10 is >5 mm 5
  • Patients with lower baseline values may require repeated dosing 5
  • ROC curve analysis shows that post-treatment fibrinogen levels under 204.5 mg/dL predict the need for massive transfusion 5

Potential Pitfalls

  • Laboratory methods to measure fibrinogen concentration may have methodological issues, particularly in the presence of artificial colloids like hydroxyethyl starch 1
  • ROTEM provides more reliable assessment of functional fibrinogen in these situations 1
  • While thrombotic risk is a theoretical concern with fibrinogen administration, studies have shown that intra-operative fibrinogen administration does not appear to increase thrombotic risk 1

Special Populations

  • In pregnancy, fibrinogen levels <200 mg/dL are associated with severe postpartum hemorrhage, suggesting higher target levels may be needed in this population 2
  • For women with congenital fibrinogen disorders during pregnancy, maintain fibrinogen levels ≥1 g/L throughout pregnancy and ≥1.5 g/L for labor and delivery 6

References

Guideline

Fibrinogen Supplementation in Bleeding Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cryoprecipitate Dosing for Transfusion

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Fibrinogen Concentrate Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.